Tevogen Inc. (TVGNW) stock
TVGNWNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as TVGN
$0.09+0.01 (+18.24%)
Close on Oct 30, 2026Market cap $38.42MP/E –Yield –
Tevogen net income
Net income is the profit left for shareholders after every expense, interest and tax.
Tevogen's net income for the twelve months ending Jun 30, 2026 was -$21.61M. For fiscal 2025 it was -$26.28M.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$26.28M | – |
| FY2024 | Dec 31, 2024 | -$13.73M | – |
| FY2023 | Dec 31, 2023 | -$60.48M | -1471.9% |
| FY2022 | Dec 31, 2022 | $4.41M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$5.76M | – |
| Q1 FY2026 | Mar 31, 2026 | -$5.45M | – |
| Q4 FY2025 | Dec 31, 2025 | -$4.68M | – |
| Q3 FY2025 | Sep 30, 2025 | -$5.73M | – |
| Q2 FY2025 | Jun 30, 2025 | -$5.50M | – |
| Q1 FY2025 | Mar 31, 2025 | -$10.37M | -192.0% |
| Q4 FY2024 | Dec 31, 2024 | -$9.44M | – |
| Q3 FY2024 | Sep 30, 2024 | -$5.88M | – |
| Q2 FY2024 | Jun 30, 2024 | -$9.66M | – |
| Q1 FY2024 | Mar 31, 2024 | $11.26M | – |
| Q4 FY2023 | Dec 31, 2023 | -$3.63M | -238.9% |
| Q3 FY2023 | Sep 30, 2023 | -$3.90M | -342.1% |
| Q2 FY2023 | Jun 30, 2023 | -$22.18M | -10817.2% |
| Q1 FY2023 | Mar 31, 2023 | -$30.76M | – |
| Q4 FY2022 | Dec 31, 2022 | $2.61M | – |
| Q3 FY2022 | Sep 30, 2022 | $1.61M | – |
| Q2 FY2022 | Jun 30, 2022 | $207.00K | – |
| Q1 FY2022 | Mar 31, 2022 | -$25.99K | – |
| Q3 FY2021 | Sep 30, 2021 | -$115 | – |